Abstract:In this study, we described a series of N-(pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine derivatives as selective JAK2 (Janus kinase 2) inhibitors. Systematic exploration of the structure–activity relationship though cyclization modification based on previously reported compound 18e led to the discovery of the superior derivative 13ac. Compound 13ac showed excellent potency on JAK2 kinase, SET-2, and Ba/F3V617F cells (high expression of JAK2V617F mutation) with IC50 values of 3, 11.7, and 41 nM, respectively. Further mechanistic studies demonstrated that compound 13ac could downregulate the phosphorylation of downstream proteins of JAK2 kinase in cells. Compound 13ac also showed good selectivity in kinase scanning and potent in vivo antitumor efficacy with 82.3% tumor growth inhibition in the SET-2 xenograft model. Moreover, 13ac significantly ameliorated the disease symptoms in a Ba/F3-JAK2V617F allograft model, with 77.1% normalization of spleen weight, which was more potent than Ruxolitinib.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01488?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01488</a>.Binding affinities of 13ac with 365 protein kinases;1H NMR, 13C NMR, MS/MS, and HPLC spectra of compound 13ac; routine blood test in normal mice; and effect of 13ac on mouse models (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_001.pdf">PDF</a>)PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2XA4">2XA4</a> used for modeling docking in JAK2 of 13ac (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_002.pdb">PDB</a>)PDB code: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4RT7">4RT7</a> used for modeling docking in FLT3 of 18e (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_003.pdb">PDB</a>)(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_004.pdb">PDB</a>)Molecular formula strings of the prepared compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01488/suppl_file/jm0c01488_si_005.csv">CSV</a>)This article has not yet been cited by other publications.

Design, synthesis, and biological evaluation of cyano-substituted 2,4-diarylaminopyrimidines as potent JAK3 inhibitors for the treatment of B-cell lymphoma

Design, synthesis and biological evaluation of purine-based derivatives as novel JAK2/BRD4(BD2) dual target inhibitors

Design, synthesis and biological evaluation of novel benzothiadiazine derivatives as potent PI3Kδ-selective inhibitors for treating B-cell-mediated malignancies

Design, Synthesis, Biological Evaluation and Molecular Docking of Novel Metronidazole Derivatives As Selective and Potent JAK3 Inhibitors

Design, synthesis, biological activity evaluation of 3-(4-phenyl-1H-imidazol-2-yl)-1H-pyrazole derivatives as potent JAK 2/3 and aurora A/B kinases multi-targeted inhibitors

Structural optimizations on the 7H-pyrrolo[2,3-d]pyrimidine scaffold to develop highly selective, safe and potent JAK3 inhibitors for the treatment of Rheumatoid arthritis

N -(Pyrimidin-2-yl)-1,2,3,4-tetrahydroisoquinolin-6-amine Derivatives as Selective Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms

Novel Synthetic Derivatives of the Natural Product Berbamine Inhibit Jak2/Stat3 Signaling and Induce Apoptosis of Human Melanoma Cells.

Design, synthesis and biological evaluation of 2-aminopyrimidine derivatives as potent FLT3 inhibitors.

Novel Synthetic Berbamine Derivatives Inhibit Jak2/Stat3 Signaling And Induce Apoptosis Of Human Melanoma Cells

Design, Synthesis and Structure-Activity Relationship Studies of Meridianin Derivatives as Novel JAK/STAT3 Signaling Inhibitors

Discovery and rational design of 2-aminopyrimidine-based derivatives targeting Janus kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3)

Abstract 864: Novel synthetic berbamine derivatives inhibit Jak2/Stat3 signaling and induce apoptosis of human melanoma cells

TYM-3-98, a Novel Selective Inhibitor of PI3Kδ, Demonstrates Promising Preclinical Antitumor Activity in B-cell Lymphomas

Design, Synthesis and Biological Evaluation of Novel 3-Substituted Pyrazolopyrimidine Derivatives As Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors

Design and synthesis of highly selective Janus kinase 3 covalent inhibitors for the treatment of rheumatoid arthritis

Discovery of triazolo [1,5-a] pyridine derivatives as novel JAK1/2 inhibitors.

Computational insights into rational design and virtual screening of pyrazolopyrimidine derivatives targeting Janus kinase 3 (JAK3)

Design, synthesis and structure-activity relationship study of aminopyridine derivatives as novel inhibitors of Janus kinase 2

4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies

Design, synthesis, and biological evaluation of naphthoylamide derivatives as inhibitors of STAT3 phosphorylation